Marshall Wace
SGMT icon

Marshall Wace’s Sagimet Biosciences SGMT Stock Holding History

Marshall Wace’s Portfolio SGMT Stock Details SGMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-966,253
Closed -$5.04M – 3677
2026
Q1 		$5.04M Buy
966,253
+185,807
+24% +$1.04M 0.01% 1301
2025
Q4 		$4.62M Buy
+780,446
New +$5.61M ﹤0.01% 1189
2025
Q2 		– Sell
-22,265
Closed -$72.6K – 3115
2025
Q1 		$72.6K Sell
22,265
-181,517
-89% -$761K ﹤0.01% 2518
2024
Q4 		$917K Sell
203,782
-59,759
-23% -$303K ﹤0.01% 1772
2024
Q3 		$730K Buy
+263,541
New +$812K ﹤0.01% 1777
2024
Q2 		– Sell
-35,678
Closed -$193K – 2916
2024
Q1 		$193K Buy
35,678
+18,893
+113% +$136K ﹤0.01% 2238
2023
Q4 		$91K Buy
+16,785
New +$79.2K ﹤0.01% 2053

Other funds holding SGMT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $962M AUM 524.64% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return

Marshall Wace's SGMT Position: Q2 2026 in Review

Marshall Wace sold out of Sagimet Biosciences (SGMT) in Q2 2026, closing a stake of 966,253 shares — an estimated $5.04M sold.

Marshall Wace first reported a position in SGMT in Q4 2023 and held it in 7 quarters. The position peaked at $5.04M in Q1 2026. 119 funds tracked by Wall St. Rank hold SGMT as of Q2 2026.

  • Marshall Wace reported no remaining Sagimet Biosciences position as of Q2 2026 after selling out during the quarter.
  • Marshall Wace sold 966,253 Sagimet Biosciences shares in Q2 2026, an estimated $5.04M.
  • Marshall Wace first reported a position in Sagimet Biosciences in Q4 2023 and held it in 7 quarters.
  • Marshall Wace's Sagimet Biosciences position peaked at $5.04M in Q1 2026.
  • 119 funds tracked by Wall St. Rank held Sagimet Biosciences as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.